Member Info for draft

Hi Sir,

Starcom is different story than Bagir in so many aspects, so the comparison is simply wrong.
The last RNS wording might be bad choice of words, but it was mainly referring to Global situation in business environment.
We are still operating as usual and facing the existing challenges, but also opportunities that COVID-19 brought along.

Thanks,

Satisfied with reply. Onwards and upwards.

https://news.sky.com/story/coronavirus-government-to-invest-93m-to-bring-forward-opening-date-of-vaccine-manufacturing-centre-11989605

Astra has a market cap of 114 billion. And we are being used by them at their request.

10p party please.

ICMAP: Identify - applying AI this simulates a chemical expert using our proven market leading algorithm for atom-atom mapping. Atom-atom mapping of reactions constitutes essential information in computational handling of chemical reactions such as (substructure or similarity) searching, reaction center identification, reaction classification and indexing.

CLASSIFY: Cluster, Organize, Analyze - The CLASSIFY algorithm calculates topology-based reaction class codes for given reactions in electronic format. It is used to calculate formal similarity of reactions and systematic clustering of reactions in databases. In retrieval systems it is used for post-search management of large hit sets and linking of reaction information from different sources. It enables quality control and overlap studies of reactions.

ICNameRXN: Augment, Cluster - As a specific sub functionality of CLASSIFY, ICNameRXN automatically assigns name reactions (such as aldol condensation, pinacol rearrangement or dials-alder reaction) to given reactions in electronic format. Besides much simplified reaction retrieval by name instead of complex reaction substructure searching, name reaction assignment is used to characterize, cluster and manage reaction databases. Named reactions are grouped in an intuitive hierarchical chemical reaction taxonomy.

ICRXNFILTER: Clean, Correct - This is used to filter and clean up large reaction databases. It is built on a series of heuristic and machine learning based algorithms to identify erroneous, incomplete or doubtful reactions.

ICRXN - The Reaction Processing Package

Do you have millions of reaction data in your company’s Electronic Lab Notebook that might be:

Erroneous

Incomplete

Duplicated

Unstructured

Non-normalised

ICRXN is a processing package combining four components that will help scientists and cheminformaticians to

Identify

Clean

Organise

Structure

Cluster

Analyze

Augment

Correct

huge amounts of chemical reaction data in electronic format (RXN file, RD file or all other reactions formats which can be converted into these). As a result, you can identify synthetically valuable reactions.

The ICRXN bundle consists of four leading reaction processing and cleaning tools developed by InfoChem using their extensive knowledge and expertise:

ICMAP: Identify - applying AI this simulates a chemical expert using our proven market leading algorithm for atom-atom mapping. Atom-atom mapping of reactions constitutes essential information in computational handling of chemical reactions such as (substructure or similarity) searching, reaction center identification, reaction classification and indexing.

AstraZeneca will use deepmatter ai to check all its molecules for contaminants. This is huge news.

N4p has 1st mover advantage here. Patent applied for also.

See if anyone replies.

Yes Hunkymonkey. Agree your post.

https://www.bighospitality.co.uk/Article/2020/05/11/The-Future-of-Restaurants-hospitality-lockdown-reopen-London-Coronavirus-social-distancing

https://www.bighospitality.co.uk/Article/2020/05/07/Corbin-King-restaurant-london-meal-gift-voucher-scheme-to-help-staff-Coronavirus

Now that regulatory agencies are aware this problem exists, they’re pushing companies to act. Both the EMA and Health Canada have released guidelines directing the pharmaceutical industry to perform risk evaluations of all drugs and review manufacturing processes to find any risk of creating N-nitrosamine impurities. This involves all the major pharmaceutical companies, Teasdale says. AstraZeneca is evaluating its entire drug portfolio. “This is looking at all of the different risk factors, primarily focused on the chemistry but also looking at things like packaging and any contribution coming from the formulated product,” Teasdale adds.

a novacyte style rise if Nigel can prove this up. The diagnostic companies are already skyhigh market caps. This should be next up - any other companies trying to do a delivery system?

Most experts say we are 12-18 months away from an approved coronavirus disease (Covid-19) vaccine, and even longer from having one available at scale. Despite vaccine development being at this uncertain early stage, India must immediately start planning how to deliver a Covid-19 vaccine.
When a vaccine becomes available, everyone will have to run the fastest and largest mass vaccination campaign in history. India will have to vaccinate about a billion people to reach the level believed to confer herd immunity for Covid-19. Each day of the virus-driven uncertainty cripples the economy and imposes immense human costs. India should do everything we can to save a few critical days, weeks or months.
A task force on coronavirus vaccine development, drug discovery, diagnosis, and testing exists. This group’s focus is diffuse. Even in the area of vaccines, the group’s focus is primarily vaccine development, not the delivery. Immunising a billion people in a country as diverse as India will be a staggering operational challenge. To be successful, we need a powerful group to plan for vaccine delivery now.

W
ASHINGTON — The Trump administration on Friday rolled out a hyper-ambitious plan to develop and manufacture hundreds of millions of Covid-19 vaccine doses by the end of 2020, outlining an aggressive process that, if successful, would shatter conventional wisdom about the typical process for developing vaccines for emerging infectious diseases.
At a Rose Garden press conference, the president and his deputies acknowledged their goal, dubbed “Operation Warp Speed,” was lofty. Trump said the project was “risky and expensive.” Gustave Perna, a four-star general who oversees logistics for the U.S. Army, called the task “Herculean.” Moncef Slaoui, the pharmaceutical executive Trump has appointed to lead the initiative, said the goal was “extremely challenging.”But they allowed themselves little ambiguity. Mark Esper, the defense secretary, pledged to deliver a vaccine “at scale” to the U.S. and its foreign partners by the end of the year.

https://www.statnews.com/2020/05/15/trump-audacious-plan-vaccine-covid19/

Scientists are launching a major new research project in India that will help to engineer an efficient and sustainable delivery mechanism – ready to get an eventual COVID-19 vaccine to billions of people around the globe.
Researchers racing to develop, test and manufacture an effective coronavirus vaccine will also need to distribute the drug globally, but universal vaccine access is already a major challenge, particularly in low-income countries across the global South - partly due to the lack of robust cold-chains.
The Global Alliance for Vaccines and Immunization estimates that only 10% of health care facilities in the world’s poorest countries have a reliable electricity supply while in some countries less than 5% of health centres have vaccine-qualified refrigerators.
Backed by the Shakti Sustainable Energy Foundation, experts from the University of Birmingham and Heriot-Watt University, Edinburgh are joining forces with non-profit, commercial and academic partners to begin investigating the scale of challenge involved in distributing a potentially temperature-sensitive COVID-19 vaccine.
Toby Peters, Professor of Cold Economy at the University of Birmingham, commented: “Universal vaccine access is already a major challenge. With COVID-19, rapid mass immunisation will probably be required; maintaining a continuous cold chain to rapidly transport and deliver COVID-19 vaccines to all communities, many where electricity supply and cooling infrastructure is often non-existent or unreliable, will be a daunting task.

https://www.birmingham.ac.uk/news/latest/2020/05/race-to-develop-covid-vaccine-delivery.aspx

He bloody fully in on this. Change of control. Hope they do actually go bust so he loses all his money.

Theres tests ,vaccine delivery system and then the vaccine. Look at the high mcaps of the test companies. This is the next step. Cant have a vaccine globally if you cant efficiently deploy it.